Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **RNU6-82P** locus encodes a **pseudogene derived from U6 small nuclear RNA (snRNA)**, which is itself a critical non-coding RNA involved in pre-mRNA splicing as a component of the spliceosome[1][2]. U6 snRNA’s true biological role is to participate in the formation of the catalytic core of the spliceosome complex, specifically facilitating excision of introns from fresh transcripts. However, **pseudogenes such as RNU6-82P do not produce functional RNAs or proteins and have no established biological activity**[5][3]. Their existence in the genome reflects historical gene duplication or retrotransposition—sometimes as chimeric products with other RNAs[5][3]. The major biological significance of these pseudogenes is to inform studies of genome evolution, retrotranspositional dynamics, and possibly transcriptome diversity, but they are *not targets for drug development nor do they play direct roles in disease, signaling, or cellular homeostasis*[5][3][1][2].
None (pseudogene, not a drug target). For clarification, the functional form of U6 snRNA is not targeted directly by any approved therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 82, pseudogene (RNU6-82P).